Please use this identifier to cite or link to this item:
|Title:||Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma||Authors:||Chung, Y.
|Keywords:||Enzyme linked immunosorbent assay
Esophageal squamous cell carcinoma
Neoadjuvant chemoradiation therapy
|Issue Date:||Jan-2011||Citation:||Chung, Y., Law, S., Kwong, D.L.W., Luk, J.M. (2011-01). Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Diseases of the Esophagus 24 (1) : 49-55. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1442-2050.2010.01093.x||Abstract:||E-cadherin is a well-documented tumor suppressor with downregulated expression in many cancer types. Upon proteolytic cleavage, a soluble form of 80-kDa degradation fragment, known as soluble E-cadherin (s-Ecad), is present in circulation; its level in sera of cancer patients is significantly associated with metastasis, recurrence, and prognosis in some malignancies. The present study investigated the association of s-Ecad with clinicopathological characteristics of patients with esophageal squamous cell carcinoma (ESCC) and its prognostic significance. A cohort of 97 patients who underwent surgery alone (n= 56) or neoadjuvant chemoradiation therapy and surgery (CRT) (n= 41) was recruited for this study. Serum samples were collected at operation (surgery group) and pre- and post-CRT treatment (CRT group) for measurement of s-Ecad protein by enzyme linked immunosorbent assay. Serum s-Ecad levels were correlated with clinicopathological parameters as well as survival. Univariate analysis showed no significant relationship between serum s-Ecad level and clinicopathological parameters for all sets of samples. Survival analysis showed that in patients who had surgical resection only, those with s-Ecad levels equal to or below the median value survived significantly longer than those with levels above the median (median survival 25.6 vs. 14.1 months, P= 0.012). Multivariate analysis showed that pathological N stage, M stage, R category, and serum s-Ecad level were significant independent prognostic factors for ESCC patients who underwent surgery only. The hazard ratio for s-Ecad was 1.104 (95% CI: 1.026-1.187) and P= 0.008. Serum s-Ecad was detected in ESCC patients and its potential as an independent prognostic marker requires further investigation. © 2010 © the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.||Source Title:||Diseases of the Esophagus||URI:||http://scholarbank.nus.edu.sg/handle/10635/125654||ISSN:||11208694||DOI:||10.1111/j.1442-2050.2010.01093.x|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 17, 2022
WEB OF SCIENCETM
checked on May 17, 2022
checked on May 12, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.